Leukocytes: The Hidden Threats in Transfusion and the Lifesaving Role of Leukoreduction
Maxime Dely, Global Expert in Blood Processing & Therapeutic Apheresis, shared an insightful post on LinkedIn:
“Leukocytes: the invisible enemies of transfusion
I remember a patient we’ll call Laurent, 67 years old, who came in for a red blood cell transfusion due to severe anemia. Everything seemed under control… until two hours after the transfusion. Chills, sudden fever, blood pressure dropping.
On the surface, the blood unit looked perfect. Test results were normal. Yet an invisible culprit was there: leukocytes.
These white blood cells, vital allies in the donor’s body, can become real saboteurs in the recipient.
They can trigger:
- Febrile non-hemolytic transfusion reactions
- Alloimmunization that complicates future transfusions
- Unpredictable inflammatory reactions
This is where leukoreduction comes in: filtering the blood within hours after donation to remove more than 99.9% of these cells. A discreet step, but one that changes everything.
Since leukoreduction became standard practice in many transfusion systems, incidents like Laurent’s have become rare. But rare doesn’t mean impossible — and each case reminds us why this measure exists.
We’ve already discussed filtration in a previous article, but it’s important to remember that not all countries or organizations have the financial or equipments to access this technology.
In an upcoming article, we’ll see that centrifugation remains the first essential step toward leukoreduction, especially in settings with limited financial or material resources.
And you — do you think universal leukoreduction should be mandatory worldwide?”
Follow the newest insights in hematology with Hemostasis Today.
-
Mar 16, 2026, 19:16Maha Othman: Delighted to See Our Article Receive The Eberhard F. Mammen Most Popular Article Award 2026
-
Mar 16, 2026, 19:03Limited Evidence for Anticoagulation Despite High VTE Risk in Sickle Cell Disease – RPTH
-
Mar 16, 2026, 18:59Bartosz Hudzik: Choosing The Right Anticoagulant for Acute Venous Thromboembolism
-
Mar 16, 2026, 18:54Michael Recht Appointed Chief Medical and Scientific Advisor to NBDF’s Pathway to Cures
-
Mar 16, 2026, 18:46David McIntosh: Moving Beyond Doubts and Ensuring the Safety of Plasma Donation
-
Mar 16, 2026, 18:42Ramy Abdelnaby: Exploring Advances in Antithrombotic Therapy for Noncardioembolic Ischemic Stroke
-
Mar 16, 2026, 18:27Christina (Tina) P: Help Advance Research and Support Patients with Antiphospholipid Syndrome
-
Mar 16, 2026, 18:20Ahmed Koriesh: Stroke Prevention in the New 2026 ACC/AHA Dyslipidemia Guideline
-
Mar 16, 2026, 18:13Nameer Ascandar: Outcomes After GI Bleeding in Patients with Rheumatoid Arthritis and AF on Long-Term Oral Anticoagulation